Buscar
Mostrando ítems 1-1 de 1
Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse
(CANCER INTELLIGENCE LTD, 2019)
Introduction: 25% of Stage III colon cancer patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery and chemotherapy. We hypothesise that sub-types of MRD, defined by circulating ...